Catalyst Wire Dossier Catalyst Wire Dossier

AEG35156 (XIAP antisense oligonucleotide)

AEG35156 · Aegera Therapeutics
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AEG35156 (XIAP antisense oligonucleotide), covering 2011-07-13 to 2011-07-13. Get the full timeline:

Most recent: Clinical Trial Update: XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) [Phase 1, Phase 2]

See pricing